Jane Street Group, LLC Alzamend Neuro, Inc. Transaction History

Jane Street Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.37 - $0.71 $607 - $1,165	-1,642 Reduced 12.03%	12,009 $5,000
Q4 2022 Feb 14, 2023	BUY	$0.53 - $222.0 $7,235 - $3.03 Million	13,651 New	13,651 $7,000
Q2 2022 Aug 16, 2022	SELL	$0.82 - $1.2 $13,634 - $19,953	-16,628 Closed	0 $0
Q1 2022 May 17, 2022	SELL	$0.91 - $2.23 $20,644 - $50,589	-22,686 Reduced 57.7%	16,628 $20,000
Q4 2021 Feb 15, 2022	SELL	$1.9 - $3.08 $28,655 - $46,452	-15,082 Reduced 27.73%	39,314 $75,000
Q3 2021 Nov 16, 2021	SELL	$2.28 - $7.68 $180,870 - $609,246	-79,329 Reduced 59.32%	54,396 $168,000
Q2 2021 Aug 16, 2021	BUY	$8.12 - $13.5 $1.09 Million - $1.81 Million	133,725 New	133,725 $1.17 Million

Ticker ALZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 95,481,800
Market Cap $159M
Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.